Page 48 - Read Online
P. 48

Rath et al. J Cancer Metastasis Treat 2020;6:30  I  http://dx.doi.org/10.20517/2394-4722.2020.51                           Page 9 of 10

               Financial support and sponsorship
               None.


               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2020.


               REFERENCES
               1.   Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol
                   2017;14:549-61.
               2.   Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol 2019;12:47.
               3.   Wang Y, Zou S, Zhao Z, Liu P, Ke C, et al. New insights into small-cell lung cancer development and therapy. Cell Biol Int
                   2020;44:1564-76.
               4.   George J, Lim JS, Jang SJ, Cun Y, Ozretić L, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47-53.
               5.   Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, et al. Tumorigenicity and genetic profiling of circulating tumor cells in
                   small-cell lung cancer. Nat Med 2014;20:897-903.
               6.   Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, et al. Circulating tumor cell clustering shapes DNA methylation to enable
                   metastasis seeding. Cell 2019;176:98-112.e14.
               7.   Klameth L, Rath B, Hochmaier M, Moser D, Redl M, et al. Small cell lung cancer: model of circulating tumor cell tumorospheres in
                   chemoresistance. Sci Rep 2017;7:5337.
               8.   Hamilton G, Rath B. Role of circulating tumor cell spheroids in drug resistance. Cancer Drug Resist 2019;2:762-72.
               9.   Hamilton G, Burghuber O, Zeillinger R. Circulating tumor cells in small cell lung cancer: ex vivo expansion. Lung 2015;193:451-2.
               10.  Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, et al; IMpower133 Study Group. First-line atezolizumab plus chemotherapy
                   in extensive-stage small-cell lung cancer. N Engl J Med 2018;379:2220-9.
               11.  Pavan A, Attili I, Pasello G, Guarneri V, Conte PF, et al. Immunotherapy in small-cell lung cancer: from molecular promises to clinical
                   challenges. J Immunother Cancer 2019;7:205.
               12.  Gadgeel SM. Targeted therapy and immune therapy for small cell lung cancer. Curr Treat Options Oncol 2018;19:53.
               13.  Hamilton G, Rath B. Insights into mechanisms of tumor dissemination from circulating tumor cell lines of small cell lung cancer. J
                   Cancer Metastasis Treat 2016;2:446-52.
               14.  Baize N, Monnet I, Greillier L, Quere G, Kerjouan M, et al. Second-line treatments of small-cell lung cancers. Expert Rev Anticancer
                   Ther 2017;17:1033-43.
               15.  Kitai Y, Kawasaki T, Sueyoshi T, Kobiyama K, Ishii KJ, et al. DNA-containing exosomes derived from cancer cells treated with topotecan
                   activate a STING-dependent pathway and reinforce antitumor immunity. J Immunol 2017;198:1649-59.
               16.  Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
               17.  Namee NM, O’Driscoll L. Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer 2018;1870:123-36.
               18.  Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
               19.  De Ruiter J, Cramer SJ, Smink T, van Putten LM. The facilitation of tumour growth in the lung by cyclophosphamide in artificial and
                   spontaneous metastases models. Eur J Cancer 1979;15:1139-49.
               20.  Ormerod EJ, Everett CA, Hart IR. Enhanced experimental metastatic capacity of a human tumor line following treatment with
                   5-azacytidine. Cancer Res 1986;46:884-90.
               21.  Karagiannis GS, Pastoriza JM, Wang Y, Harney AS, Entenberg D, et al. Neoadjuvant chemotherapy induces breast cancer metastasis
                   through a TMEM-mediated mechanism. Sci Transl Med 2017;9:eaan0026.
               22.  Revesz L. Effect of tumour cells killed by X-rays upon the growth of admixed viable cells. Nature 1956;178:1391-2.
               23.  Huang Q, Li F, Liu X, Li W, Shi W, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med
                   2011;17:860-6.
               24.  Correa M, Machado J Jr, Carneiro CR, Pesquero JB, Bader M, et al. Transient inflammatory response induced by apoptotic cells is an
                   important mediator of melanoma cell engraftment and growth. Int J Cancer 2005;114:356-63.
               25.  Chang J, Bhasin SS, Bielenberg DR, Sukhatme VP, Bhasin M, et al. Chemotherapy-generated cell debris stimulates colon carcinoma
   43   44   45   46   47   48   49   50   51   52   53